Increased IL-17RA and IL-17RC in End-Stage COPD and the Contribution to Mast Cell Secretion of FGF-2 and VEGF by unknown
LETTER TO THE EDITOR Open Access
Increased IL-17RA and IL-17RC in End-Stage
COPD and the Contribution to Mast Cell
Secretion of FGF-2 and VEGF
Abraham B. Roos1,2,3*, Michiko Mori1, Harpreet K. Gura4,5, Axel Lorentz6, Leif Bjermer7, Hans Jürgen Hoffmann4,5,
Jonas S. Erjefält1 and Martin R. Stampfli2,8
Abstract
Mast cells are accumulated in advanced chronic obstructive pulmonary disease (COPD), and interleukin (IL)-17
signaling plays a role in disease progression. The expression, localization and functional relevance of IL-17 receptor
(R)A and IL-17RC was explored in COPD by immunodetection, and functional assays.
IL-17RA and IL-17RC was increased in very severe COPD, and expressed by mast cells. Increased secretion of the
pro-angiogenic basic fibroblast growth factor and vascular endothelial growth factor was observed in
vitro-maintained mast cells stimulated with IL-17A. Expression of these mediators was confirmed in end-stage
COPD. Thus, accumulation of mast cells in COPD may contribute to vascular remodeling.
Letter
The expression of IL-17A is elevated in lung tissue of
patients with chronic obstructive pulmonary disease
(COPD), and the cytokine is linked to the pathology
associated with the disease [1, 2]. In the current study,
we investigated the expression of receptors activated by
IL-17A (IL-17 receptor (R)A and IL-17RC), to determine
the responisveness to this cytokine in COPD. We used
automated immunohistochemistry to detect the expres-
sion of IL-17RA (mouse anti-IL17RA, R&D Systems,
Minneapolis, MN, USA) and IL-17RC (mouse anti-IL-
17RC, Atlas Antibodies, Stockholm, Sweden) in periph-
eral lung tissue sections obtained from a previously
characterized cohort of COPD patients and relevant
controls (Table 1) [3]. The local ethics committee in
Lund approved the study protocol, and all subjects
signed an informed consent form.
IL-17RA immunoreactivity was observed within the cyto-
plasm of cells located within the small airway submucosa,
as well as the alveolar parenchyma in both asymptomatic
controls and patients with COPD (Fig. 1a-b). The airway
epithelium displayed minimal immunoreactivity. Similarly,
while some immunoreactivity to IL-17RC was observed in
the airway epithelium, the strongest signal was observed in
cells scattered within the airway submucosa and lung par-
enchyma (Fig. 1c-d). The number of IL-17RA+ and
IL-17RC+ cells were increased specifically in very severe
(GOLD IV) COPD (Fig. 1e and f), suggesting an involve-
ment of these receptors in COPD progression. Whereas the
exact mechanism underlying increased IL-17RA/IL-17RC
in advanced COPD still remains unknown, it may involve
the pro-inflammatory milieu documented in COPD, which
may be escalated in end-stage disease.
As not only structural cells displayed immunoreactiv-
ity, co-staining techniques for different cellular markers
was next performed to determine the specific cell types
expressing IL-17RA and IL-17RC in the peripheral lung.
In accordance with previous findings, expression was
observed across different immune cell populations, in-
cluding B lymphocytes (Fig. 1h and m), as well as on
structural cells. Expression of both IL-17RA and
IL-17RC was also detected on tryptase +mast cells
(mouse anti-tryptase, Merck-Millipore, Solna, Sweden)
(Fig. 1k and p). Previous studies have documented an ac-
cumulation of mast cells in lung tissue of patients with
advanced COPD [3], although the role of mast cells in
COPD remains elusive. We thus explored the potential
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functional relevance of IL-17 receptor expression on
mast cells in COPD. To this end, CD133+ hematopoietic
stem cell progenitors were isolated (n = 5) and differenti-
ated into mast cells, in vitro, as described elsewhere [4].
105 mast cells were following 4 weeks maturation
stimulated for 8 hours with 1000 ng IL-17A (R&D
Systems, Minneapolis, MN, USA), or left unstimulated.
Lipopolysaccharide (LPS, Sigma-Aldrich) was used as a
positive control.
The in vitro-matured cells exhibited surface markers
and functionality consistent with in vivo mast cells (i.e.
expression of tryptase, chymase, c-kit and FcεR1; data
not shown) [4, 5]. In addition, mRNA transcripts of both
IL17RA and IL17RC were detected following in vitro-
maturation (data not shown), supporting a phenotypic
resemblance to pulmonary mast cells. To evaluate the
potential contribution of IL-17A responsive mast cells to
the pathology of COPD, we assessed the secretion of
proteins associated with COPD by multiplex laser bead
technology (41/11-plex Human Cytokine/Chemokine
Arrays, Eve Technologies, Calgary, Canada). In line with
previous documented ability of mast cells to produce
pro-angiogenic factors [6, 7], IL-17A stimulated the se-
cretion of fibroblast growth factor (FGF)-2 and vascular
endothelial growth factor (VEGF) (Fig. 1q and r). Al-
though the increases were relativiely small (2-fold in-
crease for FGF-2 and 1.5-fold increase for VEGF), these
observations demonstrate the potential role for mast
cells in vascular remodeling in COPD. We used a rela-
tively high concentration of IL-17A to activate mast
cells. While the biological relevance of this concentra-
tion may be debated, the levels of IL-17A may be
enriched in the pulmonary microenviroment. Further-
more, a ten fold lower dose was able to induce the
secretion of FGF-2 in a pilot study (data not shown).
Future studies investigating pulmonary mast cells
isolated from COPD patients could provide imporant
clues to the biological relevance of these initial findings.
The inflammatory mediator profile was, in contrast,
unaffected by stimulation by IL-17A. The lack of pro-
inflammatory responisveness of mast cells to IL-17A
may be explained by earler reports of enhanced effects
by other cytokines, such as TNFα, IL-1β and IL-22 [8].
Thus, future studies investigating the potential inflam-
matory response of mast cells in response to IL-17A
would benefit from including co-stimulation, or possibly
the inflammatory milieu associated with COPD.
We next investigated the immunoreactivity for FGF-2
and VEGF in lung tissue specimens from end-stage
COPD patients, to confirm expression by mast cells. In
support of the in vitro data establishing a potential role
for mast cells in the regulation of vascular growth fac-
tors in COPD, pulmonary mast cells were positive for
both FGF-2 and VEGF (Fig. 1i and j). The biological
relevance of this observation needs to be examined fur-
ther, in particular as structural cells exhibit marked
staining intensity in pulmonary tissue.
Both increased number of pulmonary vessels and vas-
cular area is observed in COPD [9]. Moreover, medial
thickness of pulmonary vessels exhibit an inverse rela-
tion to lung function, suggesting increased vascular
remodeling in advanced disease. Others have demon-
strated that extra-pulmonary mast cells participate in
vascular remodeling by the production of pro-
angiogenic factors such as FGF-2 and VEGF [6, 7]. In
addition, it was recently demonstrated that IL-17A
directly induces the production of VEGF and FGF-2
by the endothelium [10].
Table 1 Baseline demographics and clinical characteristics
Never smokers Smokers w/o COPD COPD GOLD I COPD GOLD II-III COPD GOLD IV p ANOVA
Subjects (n) 7 6 6 13 10
Gender (female/male) 5/2 4/2 3/3 2/11 6/4
Age (years) 63 ± 4.8 57 ± 3.3 67 ± 2.9 68 ± 1.9 61 ± 1.4 ns
Height (m) 1.64 ± 0.1 1.71 ± 0.1 1.74 ± 0.1 1.73 ± 0.1 1.69 ± 0.1 ns
Weight (kg) 65 ± 4.6 69 ± 4.6 69 ± 5.7 73 ± 3.1 65 ± 1.7 ns
Body mass index 24 ± 1.3 24 ± 1.0 23 ± 1.2 24 ± 1.1 23 ± 1.0 ns
Pack years N/A 43 ± 8.2 40 ± 7.6 48 ± 3.3 41 ± 3.9 ns
Smoker/ex-smoker N/A 4/2 3/3 5/8 0/10
FEV1/FVC 86 ± 5.7 79 ± 2.0 67 ± 0.9 55 ± 2.8 32 ± 2.0 <0.001
%FEV1 110 ± 6.2 98 ± 6.0 87 ± 2.3 64 ± 3.1 23 ± 1.4 <0.001
Corticosteroids (yes/no/unknown) 0/7/0 0/6/0 0/6/0 2/11/0 9/0/1
Bronchodialator (yes/no/unknown) 0/7/0 0/6/0 3/3/0 3/10/0 9/0/1
Values are mean ± standard error of mean
COPD chronic obstructive pulmonary disease, FEV1 forced expiratory volume in 1 s, (F)VC (forced) vital capacity, GOLD Global Initiative for Chronic Obstructive
Lung Disease
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Fig. 1 Elevated expression of IL-17RA and IL-17RC in end-stage COPD. Bright field micrographs of (a) interleukin (IL)-17 receptor (R)A in never
smoker, (b) IL-17RA in COPD, (c) IL-17RC in never smoking non-COPD controls and (d) IL-17RC in COPD. Number of immunopositive cells to (e)
interleukin (IL)-17RA and (f) IL-17RC in lung tissue of never smokers, smokers and patients with GOLD I-II or III-IV COPD. Horizontal line indicates
mean value. One-way ANOVA and Dunnet’s test (GraphPad Prism 6, GraphPad Software, La Jolla, CA) was used to detect differences between
GOLD IV COPD and all other groups. Clear circles: never smokers; grey circles: asymptomatic smokers, triangles (up): GOLD I COPD; triangles
(down): GOLD II COPD; squares: GOLD III; diamonds: GOLD IV COPD. n = 7-18. *p < 0.05, **p < 0.01, *p < 0.001 compared to GOLD IV COPD.
Co-immunohistochemical staining for (g-k) interleukin (IL)-17RA and (l-p) IL-17RC (DAB, brown) and cellular markers (Vina green, blue-green).
Sections were counterstained with Mayer’s Hematoxylin. Arrows in indicate double positive cells. Scale bar: 100 μm. Expression of (q) FGF-2, and
(r) VEGF in cell supernatant of stem cell-derived mast cells stimulated with 1000 ng/ml IL-17A 8 hours. Experiments were performed in triplicates
and repeated twice. Bars indicate mean value, errorbars indicate SEM. n = 5. *p < 0.05. Light micrograph of (s) fibroblast growth factor (FGF)-2
(DAB; brown) and (t) vascular endothelial growth factor (VEGF) (DAB; brown) in GOLD IV COPD. Immunoreactivity was detected by DAB (brown)
and sections were counterstained with Mayer’s Hematoxylin (blue). Mast cells were identified by immunodetection of tryptase (Vena green;
green-blue). Arrows indicate FGF-2 and VEGF positive mast cells. Scale bar indicates 100 μm
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The current data support increased IL-17 signaling in
end-stage COPD, and stimulation of mast cell-derived
vascular growth factors by IL-17A. Together, these find-
ings designate a potential function for mast cells in ad-
vanced COPD, and warrant additional studies with the
ultimate objective to target mast cells to reduce the mor-
bidity associated with COPD.
Acknowledgements
The authors would like to thank Joanna Kasinska, Marie Bailey (McMaster
University, Hamilton, Canada), Britt-Marie G Nilsson, Karin Jansner (Lund
University, Lund, Sweden), Ellen Margrete Raaby and Beatriz Seville-Jensen
(Aarhus University, Denmark) for excellent technical support.
Funding
Canadian Institutes of Health Research (MOP-64390 and MOP-87517), the
Swedish Heart-lung Foundation, the Swedish Research Council, the Swedish
Society for Medical Research. The funding sources had no influence on study
design, sample collection, data analysis and interpretation, or preparation of
this manuscript.
Availability of data and materials
The datasets generated during and/or analysed during the current study are
available from the corresponding author on reasonable request.
Authors’ contributions
Conception and design: ABR, MM, HKG, LB, AL, JSE, HJH and MRS. Acquisition
of data: ABR, MM, HKG, LB. Analysis and interpretation: ABR, MM, HKG, AL, LB,
JSE, HJH and MRS. Drafting the manuscript for important intellectual content:
ABR, MM, HKG, LB, AL, JSE, HJH and MRS. All authors approved the final
version to be published.
Competing interests
ABR is employed by AstraZeneca. There are no other competing interest
with regard to this manuscript to declare.
Consent for publication
Not applicable.
Ethics approval and consent to participate
Informed consent was obtained from all subjects within the study. The local
research ethics board in Lund, Sweden approved the study protocol and
written consent form.
Financial Support
Canadian Institutes of Health Research (MOP-64390 and MOP-87517), the
Swedish Heart-lung Foundation, the Swedish Research Council, the Swedish
Society for Medical Research.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Department of Experimental Medical Science, Lund University, Lund,
Sweden. 2Department of Pathology and Molecular Medicine, McMaster
Immunology Research Centre, McMaster University, Hamilton, ON, Canada.
3AstraZeneca R&D Gothenburg, Respiratory, Inflammation and Autoimmunity,
Innovative Medicines, Pepparedsleden 1, 431 83 Mölndal, Sweden.
4Department of Respiratory Diseases and Allergy, Aarhus University Hospital,
Aarhus, Denmark. 5Department of Clinical Medicine, Aarhus University,
Aarhus, Denmark. 6Department of Nutritional Medicine, University of
Hohenheim, Stuttgart, Germany. 7Department of Respiratory Medicine and
Allergology, Lund University, Lund, Sweden. 8Department of Medicine,
Firestone Institute of Respiratory Health at St. Joseph’s Health Care, Hamilton,
ON, Canada.
Received: 10 February 2017 Accepted: 2 March 2017
References
1. Roos AB, Sanden C, Mori M, Bjermer L, Stampfli MR, Erjefalt JS: IL-17A Is
Elevated in End-Stage Chronic Obstructive Pulmonary Disease and
Contributes to Cigarette Smoke-induced Lymphoid Neogenesis. Am J Respir
Crit Care Med. 2015;191(11):1232-41.
2. Roos AB, Sethi S, Nikota J, Wrona CT, Dorrington MG, Sanden C, Bauer CM,
Shen P, Bowdish D, Stevenson CS, et al. IL-17A and the Promotion of
Neutrophilia in Acute Exacerbation of Chronic Obstructive Pulmonary
Disease. Am J Respir Crit Care Med. 2015;192(4):428–37.
3. Andersson CK, Mori M, Bjermer L, Lofdahl CG, Erjefalt JS: Alterations in lung
mast cell populations in patients with chronic obstructive pulmonary
disease. Am J Respir Crit Care Med. 2010;181(3):206–17.
4. Andersen HB, Holm M, Hetland TE, Dahl C, Junker S, Schiøtz PO, Hoffmann
HJ. Comparison of short term in vitro cultured human mast cells from
different progenitors — Peripheral blood-derived progenitors generate
highly mature and functional mast cells. Journal of Immunological Methods.
2008;336(2):166–74.
5. Hoffmann HJ, Frandsen PM, Christensen LH, Schiotz PO, Dahl R. Cultured
human mast cells are heterogeneous for expression of the high-affinity IgE
receptor FcepsilonRI. Int Arch Allergy Immunol. 2012;157(3):246–50.
6. Zanini A, Chetta A, Saetta M, Baraldo S, D'Ippolito R, Castagnaro A, Neri M,
Olivieri D. Chymase-positive mast cells play a role in the vascular
component of airway remodeling in asthma. Journal of Allergy and Clinical
Immunology. 2007;120(2):329–33.
7. Norrby K. Mast cells and angiogenesis. APMIS. 2002;110(5):355–71.
8. Onishi RM, Gaffen SL. Interleukin-17 and its target genes: mechanisms of
interleukin-17 function in disease. Immunology. 2010;129(3):311–21.
9. Zanini A, Chetta A, Saetta M, Baraldo S, Castagnetti C, Nicolini G, Neri M,
Olivieri D. Bronchial vascular remodelling in patients with COPD and its
relationship with inhaled steroid treatment. Thorax. 2009;64(12):1019–24.
10. Takahashi H, Numasaki M, Lotze MT, Sasaki H. Interleukin-17 enhances bFGF-
, HGF- and VEGF-induced growth of vascular endothelial cells. Immunology
letters. 2005;98(2):189–93.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Roos et al. Respiratory Research  (2017) 18:48 Page 4 of 4
